Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial
{{output}}
Introduction: EPIC-IC was a randomized, double-blind trial comparing the approved 5-day regimen of nirmatrelvir-ritonavir (NMV/r) vs. 10-day and 15-day NMV/r in immunocompromised individuals with mild-to-moderate COVID-19. We des... ...
